Post by
GameChangerBet on May 20, 2021 3:41pm
Markets
The general markets are currently experiencing a rotation is assets.
High risk, tech, health care, growth stocks are selling off. That money is flowing into value, high yields, and gold, and predominatly junior gold stocks. This rotation is well under way, but still in the early stages. This is why you are seeing stocks like Tesla, bitcoin, selling off.
ATE can certainly experience downward momentum in the short term as this rotation continues, certain price points are not impossible.
However, in ATE's case specifically, due to the number of expected positive developments, both in the near term and further out, it should be able to maintain a certain bottom price level until such developments are brought to market.
Comment by
Actuarial on May 20, 2021 4:43pm
The only part I don't like DL is his selling his shares after PH2B. The latest bought deal is fine as the price is not too bad and the sufficent fund leave us some time room for negotiation.
Comment by
markymark11 on May 21, 2021 1:59am
Sigh... I wish I hadn't looked into Cassava Sciences, because now I'm very jealous of what they were able to achieve compared to Antibe. Cassava was able to get their valuation to over $1 billion on interim phase 2 data (not even the final results yet..). Antibe needs to step up their game..
Comment by
Doccole on May 21, 2021 5:51am
That's on leadership and execution. At least we have the science. hope a deal bounces higher than agen!
Comment by
StockingUp21 on May 21, 2021 7:49am
No effort made to make us like them before multiple dilution hurts the future.
Comment by
Doccole on May 21, 2021 8:29am
I don't think covid is going to be a issue for the study. I was worried, but all our American hospitals are being told business as usual within 3 months. ATE being aligned with AH is huge. I am glad that's done. I anticipate a LATAM deal announced within 2 months with GUD.
Comment by
Doccole on May 21, 2021 9:37am
From your talks with Dan- do you think a chance of buyout has increased ? Or are we still looking at partnership?
Comment by
Actuarial on May 21, 2021 10:03am
ATE has not determine lowest effective dose yet. I see this be a key for BP to consider parnership deal or buy out.
Comment by
MrMugsy on May 21, 2021 11:05am
Yes - absolutely ... and I hope we learn about a lower dose when we're on the NASDAQ. Would be exciting information at that time.
Comment by
Edou111 on May 21, 2021 9:36am
"a liar destroyed PH1" Can you explain ? Thanks
Comment by
Actuarial on May 21, 2021 9:41am
Someone who participate Ph1 lied to ATE about his existing liver disease. And later on, show severe adverse effect in high dose (1400mg?) group and was sent to hospital. ATE halt the clinical trial and lose more than 90% of market cap in single day.
Comment by
MrMugsy on May 21, 2021 2:49pm
Depending when we actually come to market ... if later than expected for any delay ... we will get a minimum of 5 years in USA and 7 years in Europe (or shomething like that). That's all I meant by that comment. No drugs to date have impressed - agreed - but I'm banking on H2S making a big difference as per the studies on H2S for AD as we shared here in the past.
Comment by
MrMugsy on May 21, 2021 5:29pm
Exellent - Thanks Markymark. That makes comparing easier. So imagine if we could develop a drug that gets to the brain cells and provides the deficient H2S where it's needed ... along with an active ingredient like an off-patent Rivastigmine. Can't wait to see how we might perform in that arena ! It all takes time but if we're lucky ... well worth the wait. : )
Comment by
StockingUp21 on May 21, 2021 7:47am
Leadership means more than science in some case. There is not a leader here